Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
3
self-reported band not used
Founded
2021
5 years
Legal entities
1
ACRA
Office countries
1
1 address
Funding rounds
None on record
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
EXIMMIUM PTE. LTD.Entity record →
UEN202112907K
Legal entities
Show as table · Eximmium Pte. Ltd.: 1 registry entity
| EXIMMIUM PTE. LTD. | UEN 202112907K |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Eximmium is a pioneering clinical-stage biotech company based in Singapore and Munich, advancing first-in-class cancer immunotherapies that target externalized intracellular neoantigens.
Eximmium discovers and develops first-in-class (FIC) antibodies targeting intracellular proteins that are abnormally externalized on the surface of cancer cells—yet absent from normal cell membranes. This novel approach addresses the limitations of conventional immunotherapies, which often target membrane receptors or transport proteins and suffer from off-tumor toxicity and narrow therapeutic windows.
By achieving high tumor specificity and broad druggability, Eximmium’s platform supports multiple therapeutic modalities, including TCEs, ADCs, CAR-T, and RIT, with broad applicability across solid tumors.
The lead target has been clinically validated through CAR-T therapy for both efficacy and safety, and the corresponding ADC product candidates have demonstrated outstanding preclinical efficacy and safety in models of tumors (e.g. SCLC and PDAC CDX).
Backed by comprehensive validation and strong proprietary IP covering the targets, antibodies, and therapeutic applications, Eximmium is well-positioned for development and commercialization partnerships.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SG21 Biopolis Road; #05-01/02 North Tower, Nucleos; Singapore, 138567Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
1 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under Eximmium Pte. Ltd.?
One Singapore entity on ACRA: EXIMMIUM PTE. LTD. (UEN 202112907K), high confidence.
How many people work at Eximmium Pte. Ltd.?
3 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does Eximmium Pte. Ltd. have offices?
One address on record, Singapore only. Primary: 21 Biopolis Road, #05-01/02 North Tower, Nucleos, Singapore 138567.
Has Eximmium Pte. Ltd. raised funding?
None linked to this brand.
Which companies are listed alongside Eximmium Pte. Ltd.?
1 profile lists Eximmium Pte. Ltd. as a peer — 30th percentile in Biotechnology Research. It lists ten peers of its own. Twain Therapeutics lists it back.